Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13736754 | 0.84 | HDAC1 (0.53) | HDAC1HDAC3HDAC2KMT2ANCOR2 | |
| SCHEMBL9411352 | 0.78 | ACKR3 (0.56) | KMT2ADPP4DPP7OPRL1 | |
| SCHEMBL13833516 | 0.74 | HDAC1 (0.84) | HDAC1HDAC3HDAC2 | |
| SCHEMBL7929398 | 0.72 | HDAC1 (0.74) | HDAC1HDAC3HDAC2NCOR2HDAC8 | |
| SCHEMBL9247297 | 0.72 | KMT2A (0.52) | KMT2A | |
| SCHEMBL22951077 | 0.72 | HDAC1 (0.70) | HDAC1HDAC3HDAC2NCOR2HDAC8 | |
| SCHEMBL27757715 | 0.72 | HDAC1 (0.62) | HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL2618087 | 0.71 | HDAC1 (0.64) | HDAC1HDAC3HDAC2NCOR2HDAC8 | |
| SCHEMBL15785129 | 0.70 | ACKR3 (0.52) | DPP4DPP7OPRL1 | |
| SCHEMBL22716710 | 0.70 | KDM4E (0.52) | HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAc Therapeutics, Inc. | 2021-06-17 | — | — | US | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190216754-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAC THERAPEUTICS INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-9365498-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| EP-2701699-A1 | INHIBITORS OF HISTONE DEACETYLASE | The Broad Institute, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149540-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE INC (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149540-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE INC (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 7/4885HDAC2 1/4885 |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC7 | HDAC1 2/4885HDAC3 1/4885HDAC2 4/4885 |
| US-10662199-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 7/4885HDAC2 1/4885 |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 7/4885HDAC2 1/4885 |
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 7/4885HDAC2 1/4885 |
| US-20190216754-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC7 | HDAC1 2/4885HDAC3 1/4885HDAC2 4/4885 |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 7/4885HDAC2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.